Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Profound Medical Corp.

NASDAQ: PROF · Industrial Applications and Services · 9 alerts · CIK 1628808

Profound Medical Corp. stories on ALFA USA NewsRead the news →
Share price
$7.34Close, Nov 16
Market cap
$269M
Shares outstanding
36.63MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Profound Medical Corp. filings on SEC EDGAR ↗

8:08 AM ET 8-K
Leadership Change

Profound Medical Leadership Change

Profound Medical Corp. announced a leadership transition where Richard R. Fabian will succeed Arun Menawat as President and CEO effective January 15, 2027, with Dr. Menawat becoming Executive Chairman. Additionally, Jason Mills was appointed to the Board of Directors following the resignation of Cynthia Lavoie.

8:01 AM ET 8-K
Investor Presentation

Profound Medical Investor Presentation

Profound Medical announced that its management team, including President Richard Fabian, CEO Arun Menawat, and CFO Matthew Sobczyk, will participate in the Stifel 2026 Healthcare Conference in New York City. Mr. Fabian is scheduled to deliver a formal presentation on November 12, 2026, and the team will conduct one-on-one meetings with institutional investors.

5:23 PM ET 10-Q
Financial Results

Profound Medical Q3 2026 Results: Net Loss of $7.72M, Loss Narrows

For the nine months ended September 30, 2026, Profound Medical Corp. reported total revenue of $17.65 million, a significant increase from $10.12 million in the prior year, driven largely by capital equipment sales. Despite the revenue growth, the company recorded a net loss of $24.32 million, though this was an improvement over the $34.40 million loss in the same period of 2025.

Key figure
Net loss $7.72M
4:19 PM ET 8-K
Financial Results

Profound Medical Financial Results

Profound Medical reported Q3 2026 revenue of $9.8 million, an 86% year-over-year increase, driven by strong capital equipment sales and recurring revenue. The company achieved a 78% gross margin and significantly reduced its operating cash use by 56% sequentially. Additionally, the company announced a leadership transition with Richard Fabian appointed as CEO effective January 2027.

Term
Q3 2026

“Revenue increased 86% year-over-year, gross margin reached 78%, and operating cash use declined substantially from the second quarter. These results, together with our commercial pipeline, support our strong full-year outlook. Our priority is to convert growing physician interest, broader payer coverage and clinical evidence into system placements and recurring procedure revenue.”

Arun Menawat, Profound’s Chief Executive Officer and Chairman

“Our new Cook Medical agreement adds a key U.S. distribution channel, complementing our own sales team’s continued focus on selling TULSA-PRO for existing 1.5T and 3.0T MRI systems outside the agreement’s scope, while preserving our direct relationships for disposables and service. With experienced leadership in place and continued investment in product efficiency, we are positioning Profound to scale toward profitable growth.”

Arun Menawat, Profound’s Chief Executive Officer and Chairman
4:06 PM ET 8-K
Partnership

Profound Medical Partnership with Cook Medical Holdings LLC

Profound Medical entered into a supply and distribution agreement with Cook Medical to appoint them as a non-exclusive distributor of the TULSA-PRO system in the U.S. The partnership integrates TULSA-PRO into Cook's Copernicus program for intraoperative MRI suites, expanding Profound's sales channels while retaining direct recurring revenue from disposables and service.

Counterparty
Cook Medical Holdings LLC
Term
5 years
4:45 PM ET 8-K
Business Update

Profound Medical Business Update

Profound Medical announced that Emmy-Award winning host Montel Williams will join its 'Let’s Huddle' patient education webinar on November 5, 2026. The initiative focuses on prostate care advocacy and education, highlighting the company's TULSA Procedure as a treatment option.

8:00 AM ET 8-K
Clinical Trial Data

Profound Medical Clinical Trial Data

Profound Medical announced the presentation of five abstracts at the 15th Interventional MRI Symposium regarding its TULSA-PRO system. The data included real-world validation from the CARE Registry and Mayo Clinic, as well as results from the CAPTAIN randomized controlled trial showing superior preservation of erectile function compared to robotic radical prostatectomy.

Counterparty
Mayo Clinic
1:12 PM ET 8-K
Partnership

Profound Medical Partnership with Telix Pharmaceuticals Limited

Profound Medical Corp. entered into a co-education agreement with Telix Pharmaceuticals to advance PSMA-informed prostate care. The collaboration aims to educate physicians on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO platform. The partnership is intended to increase physician awareness, support patient selection, and expand access to the TULSA Procedure.

Counterparty
Telix Pharmaceuticals Limited
4:46 PM ET 8-K
Business Update

Profound Medical Business Update

Profound Medical announced preliminary unaudited revenue for Q3 2026, expecting a record range of $9.8 million to $10.0 million. This represents approximately 85% to 89% year-over-year growth and significantly exceeds analyst consensus estimates. The company also expects gross margins to exceed 70% for the period.

Earnings call
Nov 5, 2026, 4:30 PM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.